doi: 10.1007/s10571-025-01534-4
Es importante tener una variedad de medicamentos para tratar una enfermedad tan extendida como la obesidad en Estados Unidos, dijo la doctora Angela Fitch, directora mdica de knownwell, una empresa de atencin a la obesidad
In simple terms, GLP-1 (glucagon-like peptide-1) is a hormone that helps regulate blood sugar and appetite
States that have recently cut or restricted GLP-1 coverage for weight loss include: North Carolina (ended coverage October 2025) California, New Hampshire, and South Carolina (ending coverage January 2026) Pennsylvania (restricting coverage to non-weight-loss indications) Michigan (limiting to morbidly obese patients only) The BALANCE model will open to state Medicaid agencies as early as May 2026, which could eventually bring more uniform pricing and access
The data we currently have on cagrilintide alone come from a deeper follow-up analysis of a larger study called REDEFINE 1
However, oral GLP-1 options are not currently available in the UK